ABBOTT LABORATORIES Long-Term Debt, Maturity, after Year Five
ABBOTT LABORATORIES (ABT) had Long-Term Debt, Maturity, after Year Five of $7.40 billion as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-02-20
- 2025-12-31: Long-Term Debt, Maturity, after Year Five $7.40B.
- 2024-12-31: Long-Term Debt, Maturity, after Year Five $8.00B.
- 2023-12-31: Long-Term Debt, Maturity, after Year Five $8.00B.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $8.70B.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-12-31 | $7.40B 10-K · filed 2026-02-20 |
| 2024-12-31 | $8.00B 10-K · filed 2025-02-21 |
| 2023-12-31 | $8.00B 10-K · filed 2024-02-16 |
| 2022-12-31 | $8.70B 10-K · filed 2023-02-17 |
| 2021-12-31 | $9.30B 10-K · filed 2022-02-18 |
| 2020-12-31 | $12.50B 10-K · filed 2021-02-19 |
| 2019-12-31 | $12.50B 10-K · filed 2020-02-21 |
| 2018-12-31 | $11.80B 10-K · filed 2019-02-22 |
| 2017-12-31 | $14.30B 10-K · filed 2018-02-16 |
| 2016-12-31 | $12.90B 10-K · filed 2017-02-17 |
| 2015-12-31 | $3.50B 10-K · filed 2016-02-19 |
| 2014-12-31 | $2.40B 10-K · filed 2015-02-27 |
| 2013-12-31 | $3.30B 10-K · filed 2014-02-21 |
| 2011-12-31 | $7.80B 10-K · filed 2012-02-21 |
| 2010-12-31 | $9.80B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |